An interventional study of anal HPV screening in Anal Canal Cancer, sponsored by Karolinska Institutet. Not yet recruiting at 1 site in Sweden. Open to female participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by Karolinska Institutet · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches.
Secondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries.
Aims and purposes:
(I) Evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches.
(II) Assess the combination of Human Papilloma Virus (HPV) type and HPV ct values as a tool for stratifying clinical management (II) Investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV (III) Assess circulating HPV DNA in plasma as a highly specific pre-diagnostic biomarker for anal cancer
SUB PROJECT A Study design: Prospective register-based cohort study Study population: All women with HIV from the age of 45 attending routine appointments at the out-patient HIV departments at Karolinska University Hospital in Stockholm (n=707), the South Hospital in Stockholm (n=163), and Sahlgrenska University Hospital in Gothenburg (n=188), Sweden. Patients that fill the inclusion criteria will be identified from the National HIV registry InfCareHIV.
Overall aim: To assess if anal cancer screening, as proposed by the International Anal Neoplasia Society, is feasible (i.e. practical, acceptable, cost-effective) in women 45+ living with HIV Specific research questions
Reject log: data of women who reject inclusion Data collection: Samples will be collected at the out-patient HIV department including self-sampled vaginal swab for hrHPV testing and self-sampled anal swab for hrHPV. A blood sample will be taken for the analysis of circulating HPV DNA. Participants with positive anal hrHPV test will be referred to flexible endoscopy at Ersta diakoni (for women in Stockholm region) or HRA at the Gynecology department at Sahlgrenska University Hospital (for women in Gothenburg region) for anal cytology, anal biopsy and samples for DNA methylation markers. Treatment will be given if needed according to clinical practice. Participants with positive vaginal hrHPV will be referred to gynecologist according to clinical practice. A Case Report Form will be filled in by the research nurses and registered in Red-Cap. Demographic and clinical data will be collected from InfCareHIV and from medical records (history of cervical-, vaginal-, or vulval-dysplasia and comorbidities).
Questionnaire: The participants will answer a questionnaire (level of education, employment, sexual history, smoking) and questions on the acceptability of screening. The questionnaire will be answered by the patient online (using personal mobile phone or research I-pad), recorded with a unique study-id and automatically imported to Red-Cap. The health personnel will not have access to the answers of the questionnaires, but the health personnel will support the participants with any concerns before and after study inclusion.
HPV vaccination: All women that are treated for anal and cervical precancerous lesions within the frame of this study will be offered HPV vaccinations.
Bio bank: The swab samples and biopsies will be stored according to clinical routine in the Stockholm region biobank. The samples are managed according to the Swedish Biobanks in Medical Care Act (2023:38).
Laboratory analysis of circulating HPV DNA: Circulating HPVDNA in plasma will be measured using a digital PCR assay. Circulating HPVDNA will be isolated from 995 μl of plasma using the MP96 DNA and Viral NA Large Volume Kit with the cfNA ss 2000 protocol on the Roche MagNA Pure 96 system. Isolated circulating HPVDNA (and control human beta-globin gene) will be analyzed by a dPCR protocol.
Data analysis and statistics. Statistical analysis: Descriptive analysis will used to describe the study population and chi-square tests for categorical variables and t-tests for continuous variables will be used to compare the prevalence of hrHPV, LSIL and HSIL between subgroups (e.g. based on lowest CD4 count). Multivariable logistic regression will be used to identify factors associated with the presence of HSIL, adjusted for possible confounders such as age and smoking. The investigators will test for trends in sensitivity and specificity of circulating HPVDNA across time windows prior to HSIL/anal cancer diagnosis using logistic regression models. Power calculation: A sample size of 150-300 women will provide the investigators with 80% statistical power (assuming α=0.05) given an expected prevalence of anal hrHPV between 30-60%.Cost-effectiveness analysis will be performed assessing the medical costs for screening in comparison with the medical costs following an anal cancer diagnosis. The medical costs will include direct screening costs, follow-up and treatment costs and indirect costs such as loss of productivity. The time horizon for the analysis will be a lifetime. The primary effectiveness measure will be the number of cases of anal cancer prevented due to screening and early treatment of HSIL. Secondary outcomes will include the number of HSIL cases detected and treated, and quality-adjusted life years gained from preventing cancer progression. Using a decision tree or Markov model the investigators will simulate the natural history of anal cancer in women with HIV. The model will include different health states (e.g. no HSIL, HSIL, early-stage anal cancer, late-stage anal cancer) and transitions between these states based on screening and treatment. The Incremental Cost-effectiveness Ratio (ICER) will be calculated and expressed as cost per quality-adjusted life years or by cancer case prevented. Sensitivity analyses will be performed to test the robustness of the model. A cost-effectiveness threshold will be determined and assessment of whether the screening strategy falls below this threshold, indicating that it is cost-effective.
SUB PROJECT B Study design: Prospective register-based cohort study Study population: All women with HIV included in sub project A that were referred to HRA/flexible endoscopy.
Research questions:
1. Can self-sampled host DNA methylation markers be used for triaging the follow-up of women with HIV that have positive anal hrHPV tests?2. How do DNA methylation marker profiles compare between self-sampled anal swabs and clinician-obtained anal biopsies in women with low-grade (LSIL) versus high-grade (HSIL) squamous intraepithelial lesions? Method: Women included in sub-study A who are referred to HRA/endoscopy due to hrHPV positivity will be sampled for DNA-methylation both with a self-sampled anal swab, healthcare personnel collected anal swab and with a biopsy. Quantitative Multiplex Methylation-Specific PCR method will be used to quantify the DNA methylation in host target genes including multiple target genes.
Data analysis and statistics: Correlation between self-sampled samples and biopsies will be assessed. Differences in methylation levels across the different histological categories and HPV status will be visualized using boxplots and tested for statistical significance using the Kruskal-Wallis test, followed by pairwise Mann-Whitney U-tests, with the Bonferroni correction. For evaluation of the diagnostic performance of the markers, the investigators will perform univariable mixed-effect ordinal logistic regression for the individual markers. Power calculation: A sample size of 300 women will provide the investigators with 80% statistical power (assuming α=0.05) given an expected prevalence of LSIL of at least 30% and HSIL of 25%.
33 studies on the registry are indexed under Anal Canal Carcinoma; 8 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 67 across 30 interventional studies indexed under Anal Canal Carcinoma.
Browse Anal Canal Carcinoma studies →Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All included women will leave an anal HPV-self test
Diagnostic Test: anal HPV screening
From all included women samples will be collected at the out-patient HIV departments including self-sampled vaginal swab for hrHPV testing and self-sampled anal swab for hrHPV. A blood sample will be taken for the analysis of circulating HPV DNA.
Positive anal hrHPV test
Number of participants with positive anal hrHPV test
Time frame: at inclusion and through study completion, an average of 1 year
Low-grade (LSIL) and high-grade (HSIL) squamous intrepithelial lesions
Number of participants with Low-grade (LSIL) and high-grade (HSIL) squamous intrepithelial lesions
Time frame: at inclusion and through study completion, an average of one year
Circulating HPV DNA level in plasma
Circulating HPV DNA level in plasma
Time frame: at inclusion and through study completion, an average of one year
Host DNA methylation markers
Differences in methylation levels across the different histological categories and HPV status
Time frame: at inclusion and through study completion, an average of one year
Number of cases of anal cancer prevented due to screening and early treatment of HSIL
Number of cases of anal cancer prevented due to screening and early treatment of HSIL
Time frame: ten years
Number of HSIL cases detected and treated, and quality-adjusted life years gained from preventing cancer progression
Number of HSIL cases detected and treated, and quality-adjusted life years gained from preventing cancer progression
Time frame: four years
HPV ct levels
HPV ct levels compared to LSIL and HSIL outcomes
Time frame: at inclusion and through study completion, an average of one year
Plan to share: No — Individual data cannot be shared due to ethical restrictions. Coding and aggregated data can be shared after publication
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Dec 2028, 39 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.